Amgen's Kyprolis, J&J's Darzalex team up on myeloma survival win

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Sep 16, 2019 at 9:52 AM.

  1. #1 cafead, Sep 16, 2019 at 9:52 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,046
    Likes Received:
    3
    via After years of slow growth, Amgen’s Kyprolis finally looks poised to break the blockbuster barrier in 2019, and new data in tandem with the multiple myeloma field’s hottest drug could help boost it even further.

    Adding Johnson & Johnson’s Darzalex to a combination of Kyprolis and the steroid dexamethasone cut patients’ risk of disease progression or death by 37% compared with Kyprolis and dexamethasone alone, the Big Biotech said.

    article source
     
    Quote

Reply to Thread